Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the recommended first-line treatment strategy for patients with advanced NSCLC harboring the EGFR sensitizing mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.